Business Wire

Prometheus Materials’ Bio-Cement and Bio-Concrete Achieves 12x the Sound Absorption of Traditional Concrete in ASTM Testing

2.8.2023 15:00:00 EEST | Business Wire | Press release

Share

Prometheus Materials, a leader in sustainable building materials, announced today the achievement of remarkable results in the ASTM C423 sound-absorption testing of its ground-breaking bio-cement and bio-concrete technology. The company develops revolutionary zero-carbon building solutions that provide a superior alternative to carbon-intensive portland cement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802310284/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Prometheus Materials' superior sound-absorption performance compared to traditional concrete (Graphic: Business Wire)

The Johns Manville Technical Center in Littleton, Colorado – a world-class research and development facility – conducted the independent testing, which found that Prometheus Materials’ bio-concrete demonstrated a Noise Reduction Coefficient (NRC) of 0.60. This NRC rating indicates 60% sound absorption – twelve times that of traditional concrete.

Prometheus Materials’ initial pre-cast bio-concrete product line includes masonry units, segmented modular block and acoustic panels – where this exceptional sound-absorption characteristic will be an essential feature – as well as paving stones and grass pavers. These products are currently available strictly for select projects, with commercial availability slated for the first half of 2024.

Such unrivaled sound absorption is a cost-saving, environment-enhancing boon for various sectors. In settings where noise can be damaging or distracting, builders are often forced to rely on secondary products to achieve some measure of noise reduction. Beyond the added expense, these materials can sometimes have negative effects – including health risks. However, with Prometheus Materials’ bio-cement and bio-concrete products, such facilities can incorporate sound-absorption capabilities without additional cost, safety concerns or other drawbacks. Residential, commercial and institutional buildings, amphitheaters, music studios, highway barriers – and a vast array of other end-uses – will all benefit from this exceptional noise-reduction capability, while concurrently reducing their carbon footprint.

“Our latest ASTM testing results embody our commitment to innovative design,” said Loren Burnett, President, CEO & Co-founder of Prometheus Materials. “We’ve developed a novel material that provides a zero-carbon alternative to traditional concrete while delivering additional performance benefits and applications. We’re proud to pave the way toward a more technologically advanced and environmentally responsible future for the construction industry.”

Vishaan Chakrabarti, FAIA FRAIC – renowned architect, academic and business leader with focus on sustainable design; Founder and Creative Director of Practice for Architecture & Urbanism (PAU); and member of Prometheus Materials’ Board of Directors – was equally inspired. “Test results like these prove that Prometheus Materials has developed far more than zero-carbon concrete – which by itself is an enormous accomplishment,” he said. “With this level of sound absorption, as well as other characteristics currently being tested, it's clear that this material will offer a suite of products based on entirely redefined ideas of what concrete can be and do.”

Prometheus Materials continues to lead the charge in sustainability and innovation within the building materials sector. With these ASTM C423 sound-absorption results joining its previously secured ASTM C129 and C90 certifications – plus other features of its bio-cement and bio-concrete that are comparable or superior to traditional concrete – the company is poised to drive the construction industry toward a more cutting-edge and sustainable future.

About Prometheus Materials

Prometheus Materials provides sustainable building materials that accelerate the world’s transition to a carbon-negative future. Inspired by biological processes found in nature, the company’s process uses microalgae to produce a bio-cement that offers an alternative to carbon-intensive portland cement. When mixed with aggregate, this bio-cement forms a zero-carbon bio-concrete with mechanical, physical and thermal properties that rival those of portland cement-based concrete. Learn more about how the company enables the decarbonization of the construction industry at prometheusmaterials.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Liz Crumpacker
Antenna Group
prometheus@antennagroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release

The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye